Myovant Sciences Ltd

NYSE:MYOV   3:59:59 PM EDT
20.43
-0.24 (-1.16%)
Products

Myovant Sciences Announces FDA Approval Of Orgovyx (Relugolix)

Published: 12/18/2020 23:39 GMT
Myovant Sciences Ltd (MYOV) - Myovant Sciences Announces FDA Approval of Orgovyx™ (relugolix), the First and Only Oral Gonadotropin-releasing Hormone (gnrh) Receptor Antagonist for Advanced Prostate Cancer.
Myovant Sciences Ltd - Orgovyx is Expected to Be Available in January 2021.